Just a few months after stepping down as director of the prestigious Sanger Institute in the UK, Professor Allan Bradley has snared a $30 million venture round from The Wellcome Trust to finance a biotech he founded which promises to develop a better monoclonal antibody with the help of a genomically engineered mouse. Bradley, an internationally recognized genomics expert, helped develop a mouse model "that captures, in its engineered chromosomes, the entire diversity of the B lymphocyte component of the human immune system," says a release from the new biotech, Kymab. Release | Report